A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1511-1519

  Huang, Ya Hui ^a,b   Fang, Cheng Chieh ^b,c   Tsuneyama, Koichi ^d   Chou, Ho Yuan ^b,e   Pan, Wen Yu ^b,c   Shih, Yao Ming ^b,e   Wu, Ping Yi ^b   Chen, Yin ^b   Leung, Patrick S C ^f   Gershwin, M Eric ^f   Tao, Mi Hua ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d UNIVERSITY OF TOYAMA   (Japan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adeno associated virus; Hepatitis B virus; Hepatocellular carcinoma; Mouse model

Indexed keywords

ADENO ASSOCIATED VIRUS SEROTYPE 8 VECTOR; ADENOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HEPATITIS B; IMMUNOCOMPETENCE; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRION;

ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANS-SPLICING; VIRAL LOAD;

EID: 80054808952     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1145     Document Type: Article

References (49)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
2. Ganem D and Prince AM: Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350: 1118-1129, 2004. (Pubitemid 38298992)
3. Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884, 2006. (Pubitemid 43980482)
4. Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
5. Tokino T, Tamura H, Hori N and Matsubara K: Chromosome deletions associated with hepatitis B virus integration. Virology 185: 879-882, 1991.
6. Murakami Y, Saigo K, Takashima H, et al.: Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54: 1162-1168, 2005. (Pubitemid 41025914)
7. Muroyama R, Kato N, Yoshida H, et al.: Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol 45: 805-812, 2006. (Pubitemid 44646684)
8. Ferrari C, Missale G, Boni C and Urbani S: Immunopathogenesis of hepatitis B. J Hepatol 39 (Suppl 1): S36-S42, 2003. (Pubitemid 37222646)
9. Guidotti LG and Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1: 23-61, 2006.
10. Shouval D, Chakraborty PR, Ruiz-Opazo N, et al.: Chronic hepatitis in chimpanzee carriers of hepatitis B virus: morphologic, immunologic, and viral DNA studies. Proc Natl Acad Sci USA 77: 6147-6151, 1980. (Pubitemid 11206359)
11. Dandri M, Volz TK, Lutgehetmann M and Petersen J: Animal models for the study of HBV replication and its variants. J Clin Virol 34 (Suppl 1): S54-S62, 2005. (Pubitemid 43197749)
12. Guidotti LG, Matzke B, Schaller H and Chisari FV: High-level hepatitis B virus replication in transgenic mice. J Virol 69: 6158-6169, 1995.
13. Yang PL, Althage A, Chung J and Chisari FV: Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 99: 13825-13830, 2002. (Pubitemid 35215465)
14. Huang LR, Wu HL, Chen PJ and Chen DS: An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 103: 17862-17867, 2006.
15. Larkin J, Clayton M, Sun B, et al.: Hepatitis B virus transgenic mouse model of chronic liver disease. Nat Med 5: 907-912, 1999. (Pubitemid 29372417)
16. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J and Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859, 2002. (Pubitemid 34994488)
17. Xiao X, Li J and Samulski RJ: Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232, 1998. (Pubitemid 28100780)
18. Akache B, Grimm D, Pandey K, Yant SR, Xu H and Kay MA: The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80: 9831-9836, 2006. (Pubitemid 44435657)
19. Duan D, Sharma P, Yang J, et al.: Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72: 8568-8577, 1998. (Pubitemid 28471794)
20. McCaffrey AP, Fawcett P, Nakai H, et al.: The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther 16: 931-941, 2008. (Pubitemid 351587104)
21. Nayak S and Herzog RW: Progress and prospects: immune responses to viral vectors. Gene Ther 17: 295-304, 2010.
22. Wieland S, Thimme R, Purcell RH and Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101: 6669-6674, 2004. (Pubitemid 38586032)
23. Dunn C, Peppa D, Khanna P, et al.: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137: 1289-1300, 2009.
24. Chou YC, Jeng KS, Chen ML, et al.: Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol 79: 1813-1823, 2005.
25. Lai Y, Yue Y, Liu M and Duan D: Synthetic intron improves transduction efficiency of trans-splicing adeno-associated viral vectors. Hum Gene Ther 17: 1036-1042, 2006. (Pubitemid 46076745)
26. Chen CC, Sun CP, Ma HI, et al.: Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther 17: 352-359, 2009.
27. Chen SH, Hu CP and Chang CM: Hepatitis B virus replication in well differentiated mouse hepatocyte cell lines immortalized by plasmid DNA. Cancer Res 52: 1329-1335, 1992.
28. Lai Y, Yue Y, Liu M, et al.: Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 23: 1435-1439, 2005. (Pubitemid 41679397)
29. Rehermann B and Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229, 2005. (Pubitemid 40364823)
30. Moon WS, Yu HC, Chung MJ, Kang MJ and Lee DG: Pale bodies in hepatocellular carcinoma. J Korean Med Sci 15: 516-520, 2000.
31. Nakashima O, Sugihara S, Eguchi A, Taguchi J, Watanabe J and Kojiro M: Pathomorphologic study of pale bodies in hepatocellular carcinoma. Acta Pathol Jpn 42: 414-418, 1992.
32. Chisari FV, Klopchin K, Moriyama T, et al.: Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59: 1145-1156, 1989. (Pubitemid 20024625)
33. Kim CM, Koike K, Saito I, Miyamura T and Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351: 317-320, 1991. (Pubitemid 21896589)
34. Zheng Y, Chen WL, Louie SG, Yen TS and Ou JH: Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. Hepatology 45: 16-21, 2007. (Pubitemid 46144360)
35. Sette AD, Oseroff C, Sidney J, et al.: Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. J Immunol 166: 1389-1397, 2001. (Pubitemid 32060302)
36. Shimizu Y, Guidotti LG, Fowler P and Chisari FV: Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 161: 4520-4529, 1998. (Pubitemid 28492022)
37. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P and Chisari FV: Immune pathogenesis of hepatocellular carcinoma. J Exp Med 188: 341-350, 1998. (Pubitemid 28357762)
38. Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73, 2006. (Pubitemid 43042691)
39. Azam F and Koulaouzidis A: Hepatitis B virus and hepatocarcinogenesis. Ann Hepatol 7: 125-129, 2008. (Pubitemid 351845522)
40. Chisari FV and Ferrari C: Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13: 29-60, 1995.
41. Nakai H, Montini E, Fuess S, Storm TA, Grompe M and Kay MA: AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34: 297-302, 2003. (Pubitemid 36792862)
42. Miller DG, Petek LM and Russell DW: Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 36: 767-773, 2004. (Pubitemid 38886641)
43. Bell P, Moscioni AD, McCarter RJ, et al.: Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 14: 34-44, 2006. (Pubitemid 43922140)
44. Bell P, Wang L, Lebherz C, et al.: No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 12: 299-306, 2005. (Pubitemid 41025100)
45. Li H, Malani N, Hamilton SR, et al.: Assessing the potential for AAV vector genotoxicity in a murine model. Blood 117: 3311-3319, 2011.
46. Donsante A, Miller DG, Li Y, et al.: AAV vector integration sites in mouse hepatocellular carcinoma. Science 317: 477, 2007. (Pubitemid 47196106)
47. Donsante A, Vogler C, Muzyczka N, et al.: Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 8: 1343-1346, 2001. (Pubitemid 32834303)
48. Newell P, Villanueva A, Friedman SL, Koike K and Llovet JM: Experimental models of hepatocellular carcinoma. J Hepatol 48: 858-879, 2008.
49. Keng VW, Villanueva A, Chiang DY, et al.: A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 27: 264-274, 2009.